Quest diagnostics reports fourth quarter and full year 2023 financial results; provides guidance for full year 2024; increases quarterly dividend 5.6% to $0.75 per share

Fourth quarter revenues of $2.29 billion, down 1.9% from 2022 fourth quarter reported diluted earnings per share ("eps") of $1.70, up 95.4% from 2022; and adjusted diluted eps of $2.15, up 8.6% from 2022 fourth quarter base business revenues of $2.25 billion, up 4.7% from 2022 fourth quarter covid-19 testing revenues of $37 million, down 79.8% from 2022 full year revenues of $9.25 billion, down 6.4% from 2022 full year reported diluted eps of $7.49, down 6.0% from 2022; and adjusted diluted eps of $8.71, down 12.5% from 2022 full year base business revenues of $9.03 billion, up 7.1% from 2022 full year covid-19 testing revenues of $223 million, down 84.7% from 2022 full year 2024 reported diluted eps expected to be between $7.69 and $7.99; and adjusted diluted eps expected to be between $8.60 and $8.90 secaucus, n.j. , feb. 1, 2024 /prnewswire/ -- quest diagnostics incorporated (nyse: dgx), the world's leading provider of diagnostic information services, announced today financial results for the fourth quarter and full year ended december 31, 2023.
DGX Ratings Summary
DGX Quant Ranking